Close

Summit Therapeutics to Report Financial Results for the First Quarter Ended 30 April 2016 on 2 June 2016

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/26/2024

1. META
2. CMG
3. LRCX
4. IBM
5. SPY
6. HCP
7. BA
8. SNAP
9. TMUS
10. GOOGL


May 31, 2016 7:00 AM EDT

OXFORD, United Kingdom, May 31, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM: SUMM) (NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, will be reporting its first quarter financial results for the period ending 30 April 2016 on Thursday, 2 June 2016. 

About Summit Therapeutics Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease DMD and the infectious disease Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).

For more information, please contact:

Summit Therapeutics   
Glyn Edwards / Richard Pye (UK office)  Tel: +44 (0)1235 443 951
Erik Ostrowski / Michelle Avery (US office)         +1 617 225 4455
    
Cairn Financial Advisers LLP   
(Nominated Adviser)   
Liam Murray / Tony Rawlinson  Tel: +44 (0)20 7148 7900
    
N+1 Singer   
(Broker)   
Aubrey Powell / Jen Boorer  Tel: +44 (0)20 7496 3000
    
MacDougall Biomedical Communications   
(US media contact)  Tel: +1 781 235 3060
Chris Erdman / Karen Sharma  [email protected] /
   [email protected]
    
Consilium Strategic Communications   
(Financial public relations, UK)  Tel: +44 (0)20 3709 5700
Mary-Jane Elliott / Sue Stuart /  [email protected]
Jessica Hodgson / Lindsey Neville   

Source: Summit Therapeutics PLC

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Press Releases

Related Entities

Twitter, Earnings